• Home
• Mesothelioma
  • Mesothelioma Symptoms
  • What is Mesothelioma?
  • Malignant Mesothelioma
  • Mesothelioma Causes
  • Asbestos Exposure
  • Mesothelioma & Asbestos
  • Asbestos Cancer
  • Asbestos Lung Cancer
  • Non-Small Cell Lung Cancer & Asbestos
  • Small Cell Lung Cancer & Asbestos
  • Adenocarcinoma & Asbestos
  • Non-Small Cell Carcinoma & Asbestos

  • Mesothelioma Diagnosis
  • Mesothelioma Tests
  • Mesothelioma Prognosis
  • Mesothelioma Life Expectancy
  • Types of Mesothelioma
  • Pleural Mesothelioma
  • Peritoneal Mesothelioma
  • Pericardial Mesothelioma
  • Well Differentiated Papillary Mesothelioma
  • Mesothelioma Survival Rate
  • Mesothelioma Survivors
• Mesothelioma Treatment
  • Alternative Medicine
  • Mesothelioma Cure
  • Mesothelioma Research
  • Mesothelioma Foundations
  • Mesothelioma Doctors
  • Mesothelioma Oncologists
  • Types of Mesothelioma Doctors

  • Mesothelioma Cancer Centers
  • Mesothelioma Clinical Trials
• Mesothelioma Lawsuit
  • Filing a Mesothelioma Lawsuit
  • Mesothelioma Lawyer
  • Mesothelioma Attorney
  • Asbestos Lawyer
  • Financial Assistance for Patients
  • Mesothelioma Settlements
  • Mesothelioma Compensation
  • Mesothelioma Litigation
  • Mesothelioma Trust Fund
  • Mesothelioma Class Action Lawsuit
• Mesothelioma Veterans
  • Navy Veterans & Mesothelioma
  • Mesothelioma Veterans Benefits
  • Mesothelioma VA Claims

Dr. Lee M Krug

Memorial Sloan Kettering

Contact Information

• 1275 York Avenue, New York, New York 10065
• (212) 639-8420
• krugl@mskcc.org

Dr. Lee M. Krug specializes in treating mesothelioma patients. He also treats conditions such as small and non-small cell lung cancer and neuroendocrine tumors. Dr. Krug received his medical degree from St. Louis, Missouri’s Washington University School of Medicine. After obtaining his medical degree, he enrolled in an internship at John Hopkins Hospital in Baltimore, Maryland. Memorial Sloan-Kettering Cancer Center, in New York, selected Dr. Krug for a fellowship in Medical Oncology. During his time at Memorial Sloan-Kettering Cancer Center, he was honored with a Chief Fellowship in Medical Oncology.

Later in Dr. Krug’s career, he served as faculty for the American Society of Clinical Oncology (ASCO). He was given the privilege of presenting his research findings at the World Lung Cancer meetings. Currently, Dr. Krug is the Director of the Mesothelioma Program at Memorial Sloan-Kettering Cancer Center. Part of his responsibilities include organizing a team of physicians and scientists to develop and discover treatments for the disease. Dr. Krug also serves on the Scientific Advisory Board for Mesothelioma Applied Research Foundation.

The American Society of Clinical Oncology awarded a Career Development Award to Dr. Krug for his efforts in vaccination research for small cell lung cancer. Most of Dr. Krug’s mesothelioma research is through clinical trials, testing new therapies and treatment strategies for patients. Currently, he is studying the benefits of multimodal treatments in Stage I or II mesothelioma. Multimodal treatment includes chemotherapy, radiation, and surgery. Dr. Krug is also conducting a Phase III clinical trial. The trial involves the use of Vorinostat for patients with mesothelioma. In this combination therapy trial, Vorinostat is administered only to patients who have participated in chemotherapy treatment.

Dr. Krug is also studying immunology therapy, in which drugs are designed to assist the body’s natural immune system in recognizing cancer cells as foreign. When the cells are deemed foreign, then the body’s natural immune system will attack. Currently, Dr. Krug is studying ganglioside and WT-1 peptide vaccines in small cell lung cancer and mesothelioma. Both vaccines were developed by scientists in the center.

Dr. Krug has many publications to his name, in oncology and general medical journals such as the Journal of Thoracic Oncology and the European Journal of Radiology.